DiaMedica Therapeutics Inc. (DMAC)

Market Cap	163.71M
Revenue (ttm)	n/a
Net Income (ttm)	-24.44M
Shares Out	42.86M
EPS (ttm)	-0.60
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	160,051
Open	4.130
Previous Close	4.140
Day's Range	3.790 - 4.240
52-Week Range	2.140 - 6.820
Beta	1.52
Analysts	Strong Buy
Price Target	8.00 (+109.42%)
Earnings Date	Mar 17, 2025

About DMAC

DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase II/III trials for the treatment of acute ischemic stroke, as well as that is in Phase 2 to treat cardio-renal disease. The company also develops DM300, which is in preclinical stage for the treatment of severe inflammatory diseases. ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2000
• Employees: 28
• Stock Exchange: NASDAQ
• Ticker Symbol: DMAC
• Website: https://www.diamedica.com

Analyst Forecast

According to 3 analysts, the average rating for DMAC stock is "Strong Buy." The 12-month stock price forecast is $8.0, which is an increase of 109.42% from the latest price.

Price Target

$8.0

(109.42% upside)

Analyst Consensus: Strong Buy